ArticleJournal of thoracic disease2025
Comparative study of perioperative and short-to-medium-term outcomes between thoracotomy and thoracoscopy after neoadjuvant therapy for stage IIB and IIIA non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The expert consensus document on minimally invasive upper lobectomy for lung cancer in China.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The death rate of lung cancer ranks first among malignant tumors, and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases. Approximately 30% of patients are diagnosed with locally advanced disease (stage III) at the time of initial evaluation, which restricts the feasibility of direct surgical intervention. Neoadjuvant therapy has the potential to downstage tumors and enhance prognosis; however, it may also elevate surgical risks. In recent years, video-assisted thoracoscopic surgery (VATS) has gained widespread acceptance due to its minimally invasive benefits. Nevertheless, the differences in efficacy between VATS and open thoracotomy following neoadjuvant therapy remain unclear. This study aims to explore the differences in perioperative outcomes and short-to medium-term efficacy between VATS and thoracotomy in patients with NSCLC after neoadjuvant therapy. Methods: We retrospectively collected clinical data of NSCLC patients who underwent VATS and thoracotomy after neoadjuvant therapy at the Affiliated Hospital of Qingdao University from October 2018 to June 2021. We compared the perioperative outcomes and the overall survival (OS) rates over a period of 1-3 years between the two groups. Results: A total of 107 patients were enrolled, with 66 patients (61.7%) undergoing VATS and 41 patients (38.3%) undergoing thoracotomy. After propensity score matching, there were 41 cases (50.0%) in the VATS group and 41 cases (50.0%) in the thoracotomy group. VATS offers advantages such as shorter operation time, less intraoperative blood loss, less postoperative drainage volume over the first three days, shorter postoperative drainage time, and shorter postoperative hospital stay. The 3-year OS between the two surgical methods showed no statistical difference. Conclusions: Following neoadjuvant therapy for lung cancer, VATS surgery demonstrates superior perioperative outcomes compared to thoracotomy, with accelerated postoperative recovery and promising short- and medium-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.